Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ELIXSURE versus DICLOFENAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ELIXSURE versus DICLOFENAC.
CHILDREN'S ELIXSURE vs DICLOFENAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: weakly inhibits cyclooxygenase (COX) in central nervous system, reduces prostaglandin synthesis, elevates pain threshold, and acts on hypothalamic heat-regulating center to lower body temperature. Chlorpheniramine: first-generation antihistamine; competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Dextromethorphan: noncompetitive NMDA receptor antagonist and sigma-1 agonist; suppresses cough by elevating threshold in medullary cough center. Pseudoephedrine: indirectly acting sympathomimetic; releases norepinephrine from presynaptic terminals, causing vasoconstriction and nasal decongestion.
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
No established adult dose; product is specifically indicated for pediatric use only. Not recommended for adults.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
None Documented
None Documented
Clinical Note
moderateDiclofenac + Gatifloxacin
"Diclofenac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiclofenac + Rosoxacin
"Diclofenac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiclofenac + Levofloxacin
"Diclofenac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiclofenac + Trovafloxacin
"Diclofenac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life: 4–6 hours in children with normal hepatic function; prolonged to >8 hours in hepatic impairment or overdose.
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Renal elimination: ~90% as unchanged drug and active metabolite paracetamol glucuronide/sulfate conjugates; biliary/fecal: <5%.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Category C
Category D/X
NSAID
NSAID